Navigation Links
Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
Date:2/22/2010

pan> on Monday, February 22nd, until 11:59 pm ET on Monday, March 1st.  In addition, the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics.  The Company applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response.  Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia.  The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

This news release contains forward-looking statements that are subjec
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
2. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
5. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
7. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
8. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
11. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Inferior Vena Cava (IVC) Filters - ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is projected to reach US$435 million by 2016. The ... 39% (2015) of the global value while ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
(Date:12/15/2014)... and Washington State are not the ... Oregon , Alaska , and ... November 2014 elections. Photo - http://photos.prnewswire.com/prnh/20141212/164152 ... The benefits of legalizing cannabis are manifold. There are ... tax revenue for state and local governments, in addition to ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2
... 2012 The U.S. Food and Drug Administration today ... by W.L. Gore and Associates Inc. to include treatment ... aortic transection). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... endovascular graft approved by the FDA to treat a ...
... CHAPEL HILL, N.C., Jan. 13, 2012  Facing patent cliffs ... alliances - either through in-licensing deals or M&A activities ... It,s a sound strategy, but a difficult one to ... and consummating a business is fraught with potential pitfalls. ...
Cached Medicine Technology:FDA Expands Use of Endovascular Graft to Treat Aortic Tears 2Excellence Services Program Delivers a Road Map to Successfully Guide the Pharmaceutical Industry Through the New Alliance Landscape 2
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- A new ... -- moderate to severe hot flashes and night sweats ... bones. Hot flashes are common during menopause, affecting ... menopause also affect women after menopause, since they then ... "Our findings suggest women who exhibit moderate or ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... slightly reduce your risk of developing a form of ... Motrin) and naproxen (Aleve) appear to reduce the risk ... researchers concluded after reviewing nine prior studies. Squamous cell ... These painkillers "have potential as part of ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... leg for at least 20 seconds you may be at ... on one leg may indicate that small strokes or tiny ... serious strokes is high, the investigators reported online Dec. 18 ... while standing on one leg, as well as problems walking, ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... December 17, 2014 A group of 127 ... Longevity, today, in reaction to a recent statement by the ... brain training and derogated the efficacy of all brain exercises. ... with the parts of the center’s statement critical of brain ... center had also overstated its case, in a document it ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... 26 (HealthDay News) -- If you,re told that your child ... carefully consider the situation, advises an expert. "Take ... respond defensively with ,not my child., Understand that your child ... health services at Saint Joseph,s University in Philadelphia, said in ...
... high body mass index (BMI) between 9 and 12 years of ... blood insulin levels (all risk factors for developing heart disease) by ... bmj.com today. Reassuringly, say the authors, children with ... reach adolescence have better heart disease risk profiles than those who ...
... Mammals began to grow much larger after dinosaurs became extinct ... international team of researchers analyzed the fossils of major groups ... size increased from a maximum of about 10 kilograms (22 ... maximum of 17 tonnes (18.7 U.S. tons) after dinosaurs became ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... who took a popular class of heartburn drugs while ... heightened risk of birth defects, a large Danish study ... inhibitors (PPIs), include blockbusters such as Prilosec (omeprazole), Prevacid ...
... outbreaks in refugee camps in earthquake-wracked Haiti, a group ... University, and the International Vaccine Institute (IVI) have urged ... cholera vaccines for future humanitarian use. "The ... stockpile of several million doses of cholera vaccine would ...
... Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- There,s encouraging ... babies. Children whose mothers took certain anti-seizure medications while breast-feeding ... 3, a new study finds. The multi-center study looked ... common antiepileptic drugs, and found no difference in IQ levels ...
Cached Medicine News:Health News:Parents of Bullies Urged to Open Lines of Communication 2Health News:A high BMI in childhood linked to greater heart disease risk in adolescence 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 2Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 4Health News:Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests 2Health News:Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests 3
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
...
Medicine Products: